Immunoprofiler Initiative

The UCSF Immunoprofiler Initiative is an innovative sponsored research alliance backed by >$10M in funding from three global pharmaceutical companies—Bristol-Myers Squibb, Amgen, and AbbVie. Launched out of Max Krummel’s lab in the Department of Pathology, Immunoprofiler collects and analyzes flow cytometry, RNAseq, and imaging data from fresh human tumor samples to characterize their immune cell composition with the goal of improving the efficacy of immunotherapy across a wide range of cancer types. Data for at least 500 tumor samples will be collected, and sponsoring alliance members receive full access to the data to inform their own early R&D and clinical efforts in immuno-oncology. (2017 Press Release)  

Learn More